Ertapenem AptaPharma: Uses, Dosage & Side Effects
A carbapenem antibiotic for once-daily intravenous treatment of serious bacterial infections, including complicated intra-abdominal, skin, urinary tract, and pelvic infections, as well as community-acquired pneumonia
Ertapenem AptaPharma is a carbapenem antibiotic containing the active substance ertapenem. It belongs to the beta-lactam class of antibacterial agents and is used for the treatment of serious bacterial infections in adults and children aged 3 months and older. Ertapenem has a broad spectrum of activity against many Gram-positive, Gram-negative, and anaerobic bacteria, including strains producing extended-spectrum beta-lactamases (ESBLs). Its uniquely long half-life allows once-daily intravenous dosing, making it well-suited for both inpatient care and outpatient parenteral antibiotic therapy (OPAT). Ertapenem AptaPharma is a generic version of the originator product Invanz and requires a prescription.
Quick Facts: Ertapenem AptaPharma
Key Takeaways
- Ertapenem AptaPharma is a once-daily carbapenem antibiotic given as a 30-minute intravenous infusion for serious bacterial infections including complicated intra-abdominal infections, skin and soft tissue infections, community-acquired pneumonia, urinary tract infections, and pelvic infections.
- It is effective against many multi-drug-resistant Gram-negative bacteria, including ESBL-producing Enterobacterales, but does not cover Pseudomonas aeruginosa, Acinetobacter species, or MRSA – this narrower spectrum helps preserve broader carbapenems for resistant infections.
- The critical drug interaction to be aware of is with valproic acid (valproate): ertapenem can reduce valproic acid levels by 60–100%, potentially causing breakthrough seizures; concurrent use should be avoided when possible.
- Patients with a history of severe immediate-type hypersensitivity (anaphylaxis) to any beta-lactam antibiotic (penicillins, cephalosporins, or other carbapenems) should not receive ertapenem; caution is also advised in patients with central nervous system disorders due to the risk of seizures.
- As with all antibiotics, ertapenem should only be used when a bacterial infection is confirmed or strongly suspected to reduce the development of antimicrobial resistance – a growing global health threat recognized by WHO as a top priority.
What Is Ertapenem AptaPharma and What Is It Used For?
Ertapenem AptaPharma contains the active substance ertapenem (as ertapenem sodium), which belongs to the carbapenem class of beta-lactam antibiotics. Carbapenems are among the most potent and broadest-spectrum antibiotics available in clinical medicine. They are often reserved for serious infections caused by resistant bacteria that are not susceptible to narrower-spectrum agents. Ertapenem occupies a unique position within the carbapenem class because it has a somewhat narrower spectrum than other members such as meropenem, imipenem, and doripenem, notably lacking activity against Pseudomonas aeruginosa and Acinetobacter species. This targeted spectrum makes ertapenem particularly suitable for community-acquired and polymicrobial infections while helping preserve broader carbapenems for hospital-acquired multi-drug-resistant infections.
Ertapenem exerts its bactericidal activity by binding to penicillin-binding proteins (PBPs), particularly PBP-2 and PBP-3, which are essential enzymes in the bacterial cell wall biosynthesis pathway. By inhibiting these enzymes, ertapenem disrupts the cross-linking of peptidoglycan strands, the critical structural component of the bacterial cell wall. Without an intact cell wall, bacterial cells become osmotically unstable and undergo lysis (bursting) and death. A key clinical advantage of ertapenem is its remarkable stability against degradation by a wide range of beta-lactamases – the enzymes that bacteria produce to inactivate beta-lactam antibiotics. Ertapenem is resistant to hydrolysis by extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and most serine-based beta-lactamases. However, it is susceptible to metallo-beta-lactamases (MBLs) and some KPC-type carbapenemases, which are an increasing concern globally.
Another distinguishing pharmacokinetic feature of ertapenem is its long elimination half-life of approximately 4 hours, which is considerably longer than meropenem (approximately 1 hour) or imipenem (approximately 1 hour). This prolonged half-life, combined with the drug's high protein binding (approximately 95% bound to albumin), allows for once-daily dosing – a significant clinical and practical advantage. Once-daily administration improves patient convenience, reduces nursing workload in hospital settings, facilitates outpatient parenteral antibiotic therapy (OPAT) programs, and may improve treatment adherence.
Ertapenem AptaPharma is approved by regulatory authorities including the European Medicines Agency (EMA) and is indicated for the treatment of the following infections in adults and children aged 3 months and older, when caused by susceptible bacteria:
- Complicated intra-abdominal infections: These include secondary peritonitis from perforated appendicitis, bowel perforation, abdominal abscesses, and post-surgical peritonitis. Ertapenem provides coverage of the typical polymicrobial flora involved, including Escherichia coli, Bacteroides fragilis, Clostridium species, and Peptostreptococcus species. Clinical trials have demonstrated non-inferiority to piperacillin-tazobactam in this indication.
- Community-acquired pneumonia (CAP): Ertapenem is effective against the common causative organisms of CAP, including Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae (including beta-lactamase-producing strains), and Moraxella catarrhalis. However, it does not cover atypical pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, or Legionella, so additional coverage may be needed if these are suspected.
- Complicated skin and soft tissue infections (cSSTI): Including diabetic foot infections without concurrent osteomyelitis. These infections are frequently polymicrobial, involving both aerobic Gram-positive cocci and anaerobic bacteria. Ertapenem has demonstrated efficacy comparable to piperacillin-tazobactam in clinical trials involving diabetic foot infections.
- Complicated urinary tract infections (cUTI): Including acute pyelonephritis. Ertapenem has shown high clinical and microbiological cure rates in cUTI, including infections caused by ESBL-producing E. coli and Klebsiella pneumoniae, which are increasingly common worldwide.
- Acute pelvic infections: Including post-partum endomyometritis, septic abortion, and post-surgical gynecological infections. These infections typically involve a mixed aerobic-anaerobic flora for which ertapenem provides appropriate empirical coverage.
- Prophylaxis of surgical site infections following elective colorectal surgery: Ertapenem is approved for pre-operative prophylaxis when given as a single 1 g dose administered intravenously within 1 hour before the surgical incision. Studies have demonstrated significant reductions in surgical site infection rates compared with cefotetan in this setting.
It is important to note that ertapenem should only be prescribed when a bacterial infection is confirmed or strongly suspected. Unnecessary use of antibiotics contributes to the development of antimicrobial resistance, which the World Health Organization (WHO) has identified as one of the top ten global public health threats. Healthcare professionals should follow antimicrobial stewardship principles and, when possible, tailor antibiotic therapy based on culture and susceptibility results.
Ertapenem's lack of activity against Pseudomonas aeruginosa is considered a stewardship advantage. By using ertapenem instead of broader carbapenems for appropriate indications, the selective pressure for carbapenem-resistant Pseudomonas and other highly resistant organisms can be reduced. This "carbapenem-sparing" strategy is endorsed by many infectious diseases guidelines and antimicrobial stewardship programs worldwide.
What Should You Know Before Taking Ertapenem AptaPharma?
Contraindications
There are specific situations in which Ertapenem AptaPharma must not be used. Understanding these absolute contraindications is essential for safe treatment.
- Hypersensitivity to ertapenem: Do not receive this medicine if you are allergic to ertapenem sodium or to any of the other ingredients in the product.
- Hypersensitivity to other carbapenems: Patients with a known allergy to any carbapenem antibiotic (meropenem, imipenem, doripenem) should not receive ertapenem.
- Severe beta-lactam allergy: Patients who have experienced severe immediate hypersensitivity reactions (anaphylaxis, severe urticaria, angioedema, or bronchospasm) to any beta-lactam antibiotic, including penicillins and cephalosporins, should not receive ertapenem. However, patients with mild, delayed, or non-immediate penicillin allergies (such as a simple rash that developed days after starting treatment) may be able to receive ertapenem with appropriate medical supervision, as the cross-reactivity rate between carbapenems and penicillins is estimated at approximately 1% or less.
Warnings and Precautions
Seizures and other central nervous system (CNS) adverse effects have been reported with ertapenem, particularly in patients with pre-existing CNS disorders (such as brain lesions, history of seizures, or stroke), renal impairment (since ertapenem is renally excreted), or those receiving valproic acid concurrently. If seizures occur during treatment, ertapenem should be discontinued and appropriate anticonvulsant therapy initiated. Inform your doctor immediately if you experience any seizure activity, confusion, tremors, or involuntary muscle movements.
Before and during treatment with Ertapenem AptaPharma, inform your doctor if any of the following apply to you:
- Clostridioides difficile-associated diarrhea (CDAD): Antibiotic-associated colitis, including Clostridioides difficile infection, has been reported with nearly all antibacterial agents, including ertapenem. Severity can range from mild diarrhea to fatal colitis. If you develop persistent watery diarrhea, abdominal pain, or fever during or after treatment, contact your doctor immediately. Do not take anti-diarrheal medicines without consulting your healthcare provider, as they may worsen the condition.
- Hypersensitivity reactions: Serious and occasionally fatal allergic reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics including carbapenems. These reactions are more likely in patients with a history of sensitivity to multiple allergens. If an allergic reaction occurs, ertapenem must be discontinued immediately and emergency treatment initiated.
- Renal impairment: Ertapenem is primarily excreted by the kidneys. Dose adjustment is required for patients with severe renal impairment (creatinine clearance ≤ 30 mL/min) and those receiving hemodialysis. In patients with renal impairment, higher plasma levels may occur, increasing the risk of CNS side effects such as seizures.
- Central nervous system disorders: Patients with pre-existing CNS pathology (seizure disorders, brain lesions, or reduced seizure threshold) are at higher risk of CNS adverse effects. Close monitoring is recommended, and the benefits of ertapenem therapy should be weighed against potential risks.
- Hepatic impairment: Ertapenem should be used with caution in patients with liver disease. No dose adjustment is specifically recommended for mild-to-moderate hepatic impairment, but hepatic function should be monitored.
- Superinfection: Prolonged use of any antibiotic may result in overgrowth of non-susceptible organisms, including fungi such as Candida. If superinfection occurs, appropriate measures should be taken.
- Injection site reactions: Thrombophlebitis has been reported with intravenous administration. The infusion should be given slowly over 30 minutes to minimize local reactions.
Pregnancy and Breastfeeding
There are no adequate and well-controlled studies of ertapenem use in pregnant women. Animal reproduction studies have not shown evidence of harm to the fetus, but animal studies do not always predict human response. Ertapenem should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Inform your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant.
Ertapenem is excreted in human breast milk. Because of the potential for adverse effects in breastfed infants (including alteration of bowel flora and sensitization to beta-lactam antibiotics), a decision should be made whether to discontinue breastfeeding or to discontinue ertapenem, taking into account the importance of the antibiotic to the mother. Discuss the risks and benefits with your doctor.
Driving and Operating Machinery
Ertapenem may cause dizziness, somnolence (drowsiness), and, rarely, seizures or altered mental status. If you experience any of these side effects, do not drive, operate heavy machinery, or engage in activities requiring full mental alertness until the symptoms have resolved completely.
How Does Ertapenem AptaPharma Interact with Other Drugs?
Drug interactions with ertapenem are relatively limited compared with many other antibiotics, but one interaction in particular – with valproic acid – is critically important and potentially life-threatening. Healthcare providers must screen for valproic acid use before initiating ertapenem therapy. Below is a comprehensive overview of known drug interactions.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Valproic acid / Divalproex sodium | Dramatic reduction in valproic acid serum levels (60–100%), leading to loss of seizure control and potential breakthrough seizures | Avoid concurrent use; if ertapenem is essential, switch to an alternative antiepileptic drug before starting ertapenem. Increasing the valproic acid dose is unreliable and insufficient to overcome this interaction. |
| Probenecid | Inhibits renal tubular secretion of ertapenem, increasing ertapenem AUC by approximately 25% and extending its half-life | Co-administration is not recommended. The modest increase in ertapenem exposure does not warrant dose adjustment, but the combination is generally avoided. |
Minor Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Warfarin (and other coumarins) | Minor increases in INR have been reported with concurrent antibiotic use | Monitor INR closely when starting or stopping ertapenem in patients on warfarin therapy; adjust warfarin dose as needed |
| Oral contraceptives | No significant pharmacokinetic interaction demonstrated in clinical studies | No dose adjustment required; however, as with any antibiotic causing diarrhea, absorption of oral contraceptives may theoretically be affected |
| Other antibiotics (aminoglycosides, vancomycin) | No known antagonistic interaction; synergistic or additive effects may occur | Can be used in combination for broader coverage when clinically indicated; monitor renal function when combining with aminoglycosides |
| CYP450-metabolized drugs | Ertapenem does not inhibit or induce cytochrome P450 enzymes | No significant interactions expected with drugs metabolized by CYP1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 |
The interaction between carbapenems and valproic acid is one of the most clinically significant drug interactions in antimicrobial therapy. The mechanism is not fully understood but appears to involve inhibition of valproic acid glucuronide hydrolysis in the gut, preventing enterohepatic recirculation. The onset is rapid (within 24–48 hours), the magnitude is severe (often reducing valproic acid levels below the therapeutic range), and increasing the valproic acid dose is not a reliable solution. If ertapenem is required in a patient taking valproic acid, the antiepileptic drug should ideally be switched to an alternative agent (such as levetiracetam or lacosamide) before starting ertapenem.
What Is the Correct Dosage of Ertapenem AptaPharma?
Ertapenem AptaPharma is always administered by a healthcare professional as an intravenous infusion over 30 minutes. One of ertapenem's major clinical advantages over other carbapenems is its once-daily dosing schedule, made possible by its longer half-life. This simplifies treatment logistics and makes ertapenem particularly suitable for outpatient parenteral antibiotic therapy (OPAT), where patients can receive their daily infusion at home or in an infusion center rather than remaining in hospital.
Adults and Adolescents (13 Years and Older)
Standard Adult Dose
Dose: 1 g intravenously once daily
Infusion duration: 30 minutes
Treatment duration: 3–14 days depending on the infection type and clinical response
| Indication | Typical Duration | Notes |
|---|---|---|
| Complicated intra-abdominal infections | 5–14 days | Source control (surgical drainage) is essential alongside antibiotic therapy |
| Community-acquired pneumonia | 10–14 days | Switch to oral therapy (step-down) may be appropriate after clinical improvement |
| Complicated skin and soft tissue infections | 7–14 days | Including diabetic foot infections (without osteomyelitis); up to 28 days in severe cases |
| Complicated urinary tract infections | 10–14 days | Including pyelonephritis; duration of 3 days acceptable for uncomplicated cases in IV-to-oral step-down protocols |
| Acute pelvic infections | 3–10 days | Including endometritis, septic abortion, post-surgical gynecological infections |
| Surgical prophylaxis (colorectal) | Single dose | 1 g IV given within 1 hour before surgical incision; no post-operative doses needed |
Children (3 Months to 12 Years)
Pediatric Dose
Dose: 15 mg/kg intravenously twice daily (maximum 1 g/day)
Infusion duration: 30 minutes
Age restriction: Not recommended in children under 3 months of age due to insufficient safety and efficacy data
Elderly Patients
No dose adjustment is required for elderly patients with normal renal function. However, elderly patients are more likely to have reduced kidney function, so renal function should be assessed and the dose adjusted accordingly if creatinine clearance is ≤ 30 mL/min. Elderly patients may also be at slightly higher risk of CNS side effects.
Dose Adjustment for Renal Impairment
Renal Dose Adjustments
Creatinine clearance > 30 mL/min: No dose adjustment required (1 g once daily)
Creatinine clearance ≤ 30 mL/min: Reduce dose to 500 mg (0.5 g) intravenously once daily
Hemodialysis patients: 500 mg once daily; if the daily dose is given within 6 hours before hemodialysis, an additional supplementary dose of 150 mg is recommended after the dialysis session. Ertapenem is cleared by hemodialysis (approximately 30% removal).
Missed Dose
If a dose of ertapenem is missed, it should be administered as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Since ertapenem is typically administered by healthcare professionals in a supervised setting, missed doses are uncommon in clinical practice.
Overdose
There is limited experience with ertapenem overdose in humans. In clinical studies, inadvertent administration of up to 3 g per day has not resulted in clinically significant adverse effects. In the event of overdose, ertapenem should be discontinued and general supportive measures initiated. Ertapenem can be removed by hemodialysis, although there is no specific information regarding the use of hemodialysis to treat overdose. There is no specific antidote for ertapenem overdose.
Ertapenem AptaPharma is prepared and administered by trained healthcare professionals. The powder must be reconstituted with water for injection or sodium chloride 0.9% injection, and then further diluted to a final concentration of 20 mg/mL before intravenous infusion. The reconstituted and diluted solution should be used within 6 hours at room temperature or within 24 hours if stored at 2–8°C. Do not freeze.
What Are the Side Effects of Ertapenem AptaPharma?
Like all medicines, Ertapenem AptaPharma can cause side effects, although not everyone gets them. Ertapenem is generally well tolerated in clinical trials, with a safety profile comparable to piperacillin-tazobactam and ceftriaxone. The most frequently reported adverse events are gastrointestinal disturbances and local infusion site reactions. Below is a comprehensive listing organized by frequency category.
Very Common
May affect more than 1 in 10 people
- Diarrhea
- Infusion site complications (pain, swelling, redness, phlebitis, induration at the injection site)
Common
May affect up to 1 in 10 people
- Nausea and vomiting
- Headache
- Vaginitis (vaginal infection) in women
- Abdominal pain
- Rash, pruritus (itching)
- Elevated liver enzymes (ALT, AST, alkaline phosphatase)
- Thrombocytosis (elevated platelet count)
- Increased blood urea nitrogen
- Dizziness
- Somnolence (drowsiness)
- Insomnia
- Constipation
- Acid regurgitation / dyspepsia
- Edema or swelling
- Fever
- Oral candidiasis (thrush)
- Decreased white blood cell count or increased eosinophils
Uncommon
May affect up to 1 in 100 people
- Seizures
- Tremor
- Clostridioides difficile-associated diarrhea / pseudomembranous colitis
- Hypotension (low blood pressure)
- Tachycardia (rapid heartbeat)
- Dyspnea (shortness of breath)
- Altered taste (dysgeusia)
- Confusion, disorientation
- Hallucinations
- Depression
- Vertigo
- Urticaria (hives)
- Muscle weakness
- Decreased serum albumin, potassium, or sodium
- Increased blood glucose levels
Rare
May affect up to 1 in 1,000 people
- Anaphylaxis (severe allergic reaction with cardiovascular collapse)
- Angioedema (severe swelling of face, lips, tongue, or throat)
- Drug-induced hepatitis
- Pancytopenia (decrease in all blood cell types)
- Interstitial nephritis (kidney inflammation)
- Status epilepticus
- Myoclonus (sudden, involuntary muscle jerks)
Not Known
Frequency cannot be estimated from available data
- Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome)
- Encephalopathy (brain dysfunction with altered consciousness)
- Toxic epidermal necrolysis (TEN) / Stevens-Johnson syndrome (severe skin reactions)
- Erythema multiforme
Contact your doctor or seek emergency medical care immediately if you experience: signs of a severe allergic reaction (difficulty breathing, swelling of the face or throat, severe skin rash with blistering), persistent watery diarrhea with blood or mucus (possible C. difficile infection), seizures or sudden confusion, yellowing of the skin or eyes (jaundice), or severe abdominal pain.
If you experience any side effects, including those not listed here, tell your doctor or nurse. You can also report suspected side effects to your national pharmacovigilance authority (e.g., the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom) to help monitor the ongoing safety profile of ertapenem.
How Should Ertapenem AptaPharma Be Stored?
Keep this medicine out of the sight and reach of children. Do not use after the expiry date stated on the vial label and outer carton after EXP. The expiry date refers to the last day of that month.
- Unopened vials: Store below 25°C (77°F). Do not freeze.
- Reconstituted solution (not yet diluted): Should be diluted in sodium chloride 0.9% infusion solution immediately. If not used immediately, can be stored at 2°C to 8°C for up to 24 hours.
- Diluted infusion solution: Use within 6 hours at room temperature (below 25°C) or within 24 hours if stored at 2–8°C. Use within 4 hours after removal from refrigeration.
- Do not freeze the reconstituted or diluted solution.
- Inspection: The reconstituted solution should be a clear, colorless to pale yellow solution. Do not use if particles or discoloration are observed.
As Ertapenem AptaPharma is prepared and administered in a hospital, infusion center, or under the supervision of a healthcare professional, storage will typically be handled by your healthcare team and pharmacy. Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use.
What Does Ertapenem AptaPharma Contain?
Active Substance
The active substance is ertapenem. Each single-use vial contains 1.0 g of ertapenem (as ertapenem sodium). Ertapenem sodium is a white to off-white powder. The molecular formula of ertapenem sodium is C22H24N3NaO7S, with a molecular weight of approximately 497.5 daltons. Ertapenem is chemically described as [4R-[3(3S*,5S*),4α,5β,6β(R*)]]-3-[[5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, monosodium salt.
Inactive Ingredients (Excipients)
- Sodium hydroxide (E524) – for pH adjustment
Sodium Content
Each vial of Ertapenem AptaPharma contains approximately 137 mg of sodium (equivalent to approximately 6 mmol), which corresponds to approximately 6.9% of the WHO-recommended maximum daily dietary sodium intake for adults (2 g sodium per day). This should be taken into consideration by patients on a controlled sodium diet, particularly those receiving multiple doses or with conditions such as heart failure or kidney disease where sodium intake must be restricted.
Appearance
Ertapenem AptaPharma is supplied as a white to off-white lyophilized (freeze-dried) powder in a glass vial. After reconstitution with water for injection or sodium chloride 0.9% injection, the solution should be a clear, colorless to pale yellow liquid. The reconstituted solution must then be further diluted in sodium chloride 0.9% infusion solution before intravenous administration.
Frequently Asked Questions About Ertapenem AptaPharma
Ertapenem AptaPharma is a carbapenem antibiotic used to treat serious bacterial infections in adults and children aged 3 months and older. It is approved for complicated intra-abdominal infections, community-acquired pneumonia, complicated skin and soft tissue infections (including diabetic foot infections), complicated urinary tract infections (including pyelonephritis), acute pelvic infections, and for prevention of surgical site infections following elective colorectal surgery. It is effective against many multi-drug-resistant Gram-negative bacteria, including ESBL-producing strains.
Ertapenem differs from meropenem and imipenem in two key ways. First, it has a narrower spectrum – it does not cover Pseudomonas aeruginosa, Acinetobacter species, or Enterococcus species, making it more appropriate for community-acquired rather than hospital-acquired infections. Second, it has a longer half-life (approximately 4 hours vs. approximately 1 hour), allowing once-daily dosing instead of three to four times daily. This makes ertapenem particularly convenient for outpatient parenteral antibiotic therapy (OPAT). Its narrower spectrum is also considered an antimicrobial stewardship advantage, as it exerts less selective pressure for pan-resistant organisms.
Yes, seizures are a known side effect of ertapenem, though they are uncommon (affecting up to 1 in 100 patients). The risk is higher in patients with pre-existing central nervous system disorders (such as a history of seizures, brain lesions, or stroke), in patients with renal impairment (since ertapenem accumulates when kidney function is reduced), and in patients receiving valproic acid concurrently (which dramatically lowers valproate levels, removing seizure protection). If you have any of these risk factors, your doctor will carefully weigh the benefits against the risks before prescribing ertapenem.
It depends on the type and severity of your penicillin allergy. If you have had a severe immediate-type allergic reaction to penicillin (anaphylaxis, severe urticaria, angioedema, or bronchospasm), ertapenem should not be used due to the risk of cross-reactivity. However, the cross-reactivity rate between carbapenems and penicillins is estimated at only about 1% or less. For patients with mild, non-immediate penicillin allergies (such as a delayed rash), ertapenem can generally be administered safely with appropriate medical supervision. Always inform your healthcare provider about the details of your allergy, including when it occurred and what symptoms you experienced.
Diabetic foot infections are typically polymicrobial, involving a mix of aerobic Gram-positive bacteria (such as Staphylococcus aureus and Streptococcus species), aerobic Gram-negative bacteria (such as E. coli, Proteus, and Klebsiella), and anaerobic bacteria (such as Bacteroides and Peptostreptococcus). Ertapenem provides excellent coverage against all of these organism groups with a single once-daily infusion. Clinical trials comparing ertapenem to piperacillin-tazobactam in diabetic foot infections demonstrated comparable efficacy, and the convenient once-daily dosing facilitates treatment in outpatient settings, which is important since many diabetic foot infections require prolonged antibiotic courses of up to 4 weeks.
Yes, ertapenem is highly effective against infections caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, including E. coli and Klebsiella pneumoniae. ESBL-producing bacteria are resistant to most cephalosporins and many other antibiotics, making carbapenems the treatment of choice. Ertapenem is often preferred over broader carbapenems (meropenem, imipenem) for ESBL infections when Pseudomonas is not a concern, as part of antimicrobial stewardship strategies to preserve broader-spectrum agents. Multiple observational studies and some randomized trials support the efficacy of ertapenem for ESBL infections, particularly urinary tract infections and intra-abdominal infections.
References
- European Medicines Agency (EMA). Invanz (ertapenem) – Summary of Product Characteristics. Last updated 2025. Available from: EMA EPAR.
- U.S. Food and Drug Administration (FDA). Invanz (ertapenem for injection) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164. doi:10.1086/649554.
- Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. Clin Infect Dis. 2012;54(12):e132–e173. doi:10.1093/cid/cis346.
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023;ciad428. doi:10.1093/cid/ciad428.
- Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother. 2003;52(3):331–344. doi:10.1093/jac/dkg375.
- Norrby SR, Petermann W, Andrémont A, et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia. Clin Microbiol Infect. 2002;8(Suppl 1):79–80.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023.
- Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2):e00079-17. doi:10.1128/CMR.00079-17.
- European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 14.0, 2024. Available from: EUCAST.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in infectious diseases, microbiology, and clinical pharmacology.
Medical Content
iMedic Infectious Diseases Editorial Team – specialist physicians in infectious diseases with clinical experience in antimicrobial therapy
Medical Review
iMedic Medical Review Board – independent panel verifying accuracy against EMA SmPC, FDA label, IDSA, and ESCMID guidelines
Pharmacology Review
iMedic Clinical Pharmacology Team – specialists in drug interactions, pharmacokinetics, and antimicrobial stewardship
Accessibility & SEO
iMedic Digital Health Team – ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.